INNIO Technology Selected for First 100% Hydrogen Engine Power Plant in Asia Pacific
19.11.2021 09:00:00 EET | Business Wire | Press release
INNIO today announced that Hyosung Heavy Industries (Hyosung) has selected INNIO Jenbacher ‘Ready for Hydrogen’ engine technology for the first pilot power plant project in APAC that will be fueled by 100% hydrogen. The pilot hydrogen power plant will be built at the Hyosung Chemical Yongyeon Plant in Ulsan, South Korea, setting a benchmark by becoming the first 100% hydrogen power plant to be operated in the region. It will run on hydrogen produced as a byproduct at the chemical plant that is normally sold off to an industrial gas company. The project is expected to achieve commercial operation in 3Q 2022 and complete the demonstration by end of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006247/en/
Park Jeong-Ha, General Manager at Hyosung (Photo: Business Wire)
“INNIO has based its strategy on hydrogen becoming a driver of the energy transition, as it is uniquely positioned to shape a low- through no-carbon energy sector. INNIO launched its ‘Ready for Hydrogen’ portfolio to meet customers’ demands for sustainable solutions, such as at Hyosung, to establish hydrogen-based power generation. We are pleased to be their hydrogen engine technology partner of choice and to establish the first 100% hydrogen power plant in APAC,” said Olaf Berlien, president and CEO of INNIO. “We will continue our relentless focus to deliver INNIO technologies and services that will help our customers to reduce their carbon footprint down to zero.”
“Hyosung is striving to improve its impact on climate change by embracing the global energy transition. We have joined forces with INNIO to support our efforts to reduce carbon emissions while exploring commercial and sustainable opportunities related with our hydrogen byproduct production,” commented Park Jeong-Ha, General Manager at Hyosung. “Our climate change response strategies have set the goal of reducing emissions and energy consumption while increasing energy efficiency. INNIO Jenbacher provides the efficient and proven technology that helps us meet this goal.”
As a shaper of a low-carbon economy, INNIO is preparing for a secure, affordable, and climate-neutral energy future for everyone. The pilot power plant using INNIO Jenbacher technology, will be the second power plant in the 1-MW range that can be fueled with 100% hydrogen. INNIO is a hydrogen pioneer for more than 20 years, when the first Jenbacher 150-kilowatt pilot engine ran on 100 percent hydrogen at a demonstration plant in northern Germany. Two decades later, in 2020, after a number of additional demonstration projects, INNIO and HanseWerk Natur demonstrated the world’s first hydrogen engine using variable hydrogen and natural gas mixtures up to 100% hydrogen on an INNIO Jenbacher engine. The collaboration with Hyosung now marks a further milestone for INNIO to help drive the energy transition.
About INNIO
INNIO is a leading provider of renewable gas and hydrogen-rich solutions and services for power generation and compression at or near the point of use. With our Jenbacher and Waukesha products, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by sustainability, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com. Follow INNIO on Twitter and LinkedIn .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006247/en/
Contact information
Susanne Reichelt
INNIO
+43 664 80833 2382
susanne.reichelt@innio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom